Navigation Links
Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
Date:3/18/2008

PALO ALTO, Calif., March 18 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that it has expanded its senior debt under an agreement with an affiliate of Lehman Brothers and certain of the other holders of Jazz Pharmaceuticals' existing senior debt. The transaction closed with $40 million of gross proceeds, expanding the senior debt outstanding from $80 million to $120 million. The notes issued under the note and warrant purchase agreement bear interest at 15 percent per annum, payable quarterly in arrears, and are due in June 2011. In connection with this expansion, Jazz Pharmaceuticals issued to the note purchasers five-year warrants to purchase an aggregate of 562,192 shares of its common stock at an exercise price of $14.23 per share.

Jazz Pharmaceuticals has an option under the agreement, through January 31, 2009, to borrow an additional $30 million, with the issuance of additional warrants, if sales of the company's products reach certain levels by the end of 2008 and subject to customary closing conditions.

"We are pleased to have closed this significant expansion of our senior debt with Jazz Pharmaceuticals' senior lenders very quickly after the FDA's approval of LUVOX CR, together with obtaining an option for additional expansion following sales growth of our products," said Matthew K. Fust, Chief Financial Officer.

Jazz Pharmaceuticals plans to use the proceeds of the debt expansion to pay milestones due under its license agreement with Solvay Pharmaceuticals, Inc. for LUVOX(R) CR (fluvoxamine maleate) Extended-Release Capsules, to support LUVOX CR launch expenses, and for general corporate purposes.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the use of the proceeds from the debt expansion, the ability to increase the senior debt by an additional $30 million and the launch of LUVOX CR. Words and phrases such as "will," "plan," "is expected" and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Jazz Pharmaceuticals' current expectations. Forward-looking statements involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that the conditions applicable to the option to further expand the senior debt will not be satisfied in a timely manner, or at all, and risks related to when or whether commercial launch of LUVOX CR will occur and Jazz Pharmaceuticals' need for additional funding. These and other risk factors are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on November 9, 2007. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
2. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
3. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
6. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
7. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
8. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
9. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
11. Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling author ... tech companies. “Grit” author Angela Duckworth and her team at Character Lab have ... Cooley, an international law firm with decades of experience supporting high-growth companies in ...
(Date:9/19/2017)... SAN FRANCISCO , Sept. 19, 2017 ... Management Solutions (VLMS) is pleased to announce the strategic ... VTI to provide clients with validation services using the ... a partner, VTI will provide clients with efficient and ... be a marketing partner for the ValGenesis VLMS system. ...
(Date:9/19/2017)... NC (PRWEB) , ... September 19, 2017 , ... ... on band technologies for surgical applications, announced today that two new patents have ... , Michael Albert, MD, Co-Founder of Band-LOK, said, “We continue to explore additional ...
(Date:9/18/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... September 18, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... presentation at the ServiceMax Maximize 2017 conference. , What: Digital Transformation in Medical ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
Breaking Biology News(10 mins):